Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – What’s Next?

by · The Cerbat Gem

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $14.69, but opened at $13.93. Astellas Pharma shares last traded at $14.26, with a volume of 37,675 shares trading hands.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

View Our Latest Report on ALPMY

Astellas Pharma Stock Performance

The stock has a market capitalization of $25.75 billion, a PE ratio of 10.83 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The business’s fifty day moving average price is $14.15 and its 200-day moving average price is $14.59.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.

Recommended Stories